Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma (MPC) treated with FOLFIRINOX or gemcitabine (gem) in a randomized phase III study (ACCORD11/PRODIGE4).
Marie Robert(Université Claude Bernard Lyon 1), Marta Jarlier(Institut de Recherche en Cancérologie de Montpellier), Jaafar Bennouna(Hôpital Foch), Sophie Gourgou(Université de Montpellier), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(UniCancer Group), Thierry Conroy(Institut de Cancérologie de Lorraine), Marc Ychou(Université de Montpellier), Françoise Desseigne(Centre Léon Bérard)
Cited by 5
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k